Vir Biotechnology Inc . (NASDAQ:) provided a detailed update on its financial results and progress across its development programs during...
Vir
Pictured: GSK making in Dresden, Germany/iStock, 13threephotography Vir Biotechnology and GSK are ending a aspect of their collaborative effort and hard...
– Dependent on a novel human cytomegalovirus vector platform, VIR-1388 was created with the target of building a novel HIV...
SAN FRANCISCO, June 07, 2023 (Globe NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today declared that 5 abstracts highlighting new...
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Rating)'s share price gapped down prior to trading on Friday after the company announced...
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with...
